v3.26.1
Collaborations and Other Arrangements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Costs to obtain or fulfill contract capitalized   $ 0   $ 0      
Collaboration revenue   7,659,000 $ 14,245,000 22,707,000 $ 30,872,000    
Deferred revenue   0 29,693,000 0 29,693,000 $ 7,290,000 $ 38,917,000
Hemophilia Co Co Agreements              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Material costs   0 0 0 0    
Regeneron Pharmaceuticals Inc. [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred revenue   0   0   7,300,000  
Regeneron Pharmaceuticals Inc. [Member] | Related Party [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Accounts receivable   7,300,000   7,300,000   $ 9,500,000  
Regeneron Pharmaceuticals Inc. [Member] | Regeneron Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue   6,600,000 7,900,000 15,000,000 14,900,000    
Deferred revenue $ 30,000,000            
Collaboration term extension period 2026-04            
Regeneron Pharmaceuticals Inc. [Member] | 2016 Regeneron Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue   600,000 5,000,000 5,800,000 10,100,000    
AvenCell [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue   0 0 0 0    
Kyverna Therapeutics Inc [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue   $ 0 $ 0 $ 0 $ 0